Life Sciences Archives - New Science Ventures

June 6, 2020

Ventyx Biosciences

Developing selective inhibitors of TYK2 for autoimmune diseases.

January 31, 2020

Zomagen

Developer of small molecules harnessing the therapeutic potential of inflammasome modulation across autoimmune/inflammatory indications.

November 1, 2018

Morrow

Focused on the commercialization of spectacles with digital lens technology.

October 3, 2018

ChromaCure

Focused on the development of a first-in-class oncology therapeutic.

June 13, 2018

NorthSea Therapeutics

Focused on the development of first-in-class therapeutics for NASH and other metabolic, inflammatory and fibrotic diseases.

October 17, 2017

Seahorse Bioscience

Acquired by Agilent Technologies. Developer of tools for measuring cell metabolism.

October 17, 2017

K2M

Acquired by Welsh, Carson, Anderson & Stowe. Developer of solutions for the treatment of complex spinal pathologies.

October 17, 2017

FlowCardia

Acquired by C.R. Bard. Developer of endovascular devices for the treatment of coronary and peripheral CTO.

October 17, 2017

Dezima

Acquired by Amgen. Focused on the development of a small molecule therapy for dyslipidemia.

October 17, 2017

Conor Medsystems

Acquired by Johnson & Johnson. Focused on the development of drug-eluting stents to treat coronary artery disease.

October 17, 2017

Ception

Acquired by Cephalon. Focused on the development of a biologic therapy for the treatment of asthma.

October 17, 2017

Biovex

Acquired by Amgen. Focused on the development of an oncolytic vaccine for melanoma and head and neck cancer.

Sector Category: Life Sciences